Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals

AstraZeneca made a $10 billion offer for Rhythm Pharmaceuticals, according to an exclusive report from The Wall Street Journal. The reported bid puts one of the largest pharma acquisition approaches of the cycle on the table and names both companies as direct participants.

The WSJ report establishes the offer's size at $10 billion and identifies AstraZeneca as the bidder and Rhythm Pharmaceuticals as the target. That is the full extent of what is confirmed: a reported offer, not a signed deal. Whether Rhythm has accepted, rejected, or countered is not established in the report.

Interpretation: a $10 billion approach for a single targeted company signals that AstraZeneca is willing to pursue a sizable transaction rather than a bolt-on. Reported offers of this kind often precede one of several outcomes, including a negotiated agreement, a raised bid, or a rejection that becomes public. This is analysis of the situation, not new information from the report.

The exclusive framing matters for positioning. Neither company's confirmation is part of the reporting, so the market is trading on a press leak rather than an announced transaction.